Procept (PRCT): 50% rise on high volume. Why? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Procept (PRCT): 50% rise on high volume. Why?

PRCT 29.67

-2.5%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John Crovelli who wrote (8)	6/28/1996 11:47:00 AM
From: John B. Anderson	of 455

All: I own PRCT and talk frequently to one of the 2 analysts that cover the company (Mary Ann Gray at Dillon, Read). I assume you're all aware of the recent private financing that gave the company breathing space for approximately one year, the started-again Phase I/II trials in the Netherlands on PRO 2000, the anti-HIV molecule that prevents HIV from "docking" on immune system cells? Are you aware that they have a new semi-self-financing venture to develop exciting new vaccines against major diseases -- Vactex? PRCT is also shopping for a large drug-company partner (1) to sponsor and oversee trials, production and marketing of PRO 2000 as an injectable intra-vaginal protective solution preventing against AIDS and herpes (the NIH had something to do with requesting they initiate this); (2) to co-develop PRO 600 an anti-psoriasis (excuse spelling) immune-system-targeted formulation that has shown great promise in the lab. In summary, the distinguished analyst I talk to (a Ph.D. with 20 years of academic, pharmaceutical industry and brokerage-industry experience -- she has literally made me BUNDLES of money) has convinced me this company has some really exciting things going on in trials, a distinguished scientific staff, and good respect and linkage in the Harvard/Cambridge biotech community. PRCT presently has very little analytical coverage in the brokerage community. Given all these elements and Procept's TINY, TINY capitalization, PRCT stock could have a simply screeching take off --- IF --- I emphasize --- IF --- ANY of these immune system drugs/development projects/corporate partnerships catch fire! That's why I own the stock for my very aggressive, speculative portfolios. And I'm not selling. John_B_Anderson@prodigy.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next